Manjinder S.M.S.LallManjinder S.M.S. i inni, Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H1 Receptor Inverse Agonist, „Journal of Medicinal Chemistry”, 63 (13), 2020, s. 7268–7292, DOI: 10.1021/acs.jmedchem.0c00483, PMID: 32462865 [dostęp 2021-08-18](ang.).
Gai-ZhiG.Z.LiuGai-ZhiG.Z. i inni, Stereoselective synthesis of desloratadine derivatives as antagonist of histamine, „Bioorganic & Medicinal Chemistry”, 18 (4), 2010, s. 1626–1632, DOI: 10.1016/j.bmc.2009.12.061, PMID: 20110173 [dostęp 2021-08-18](ang.).
MeltonM.AffrimeMeltonM. i inni, A pharmacokinetic profile of desloratadine in healthy adults, including elderly, „Clinical Pharmacokinetics”, 41 Suppl 1, 2002, s. 13–19, DOI: 10.2165/00003088-200241001-00003, PMID: 12169042 [dostęp 2021-08-18](ang.).
NancyN.HakoozNancyN., Isam I.I.I.SalemIsam I.I.I., Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males, „Biopharmaceutics & Drug Disposition”, 33 (1), 2012, s. 15–21, DOI: 10.1002/bdd.1770, PMID: 22271705 [dostęp 2021-08-18](ang.).
Inês CristinaI.C.Camelo-NunesInês CristinaI.C., New antihistamines: a critical view, „Jornal De Pediatria”, 82 (5 Suppl), 2006, S173–180, DOI: 10.2223/JPED.1552, PMID: 17136293 [dostęp 2021-08-18](port.).
KarstenK.WellerKarstenK., MarcusM.MaurerMarcusM., Desloratadine inhibits human skin mast cell activation and histamine release, „The Journal of Investigative Dermatology”, 129 (11), 2009, s. 2723–2726, DOI: 10.1038/jid.2009.134, PMID: 19516262 [dostęp 2021-08-18](ang.).
DamianD.TworekDamianD. i inni, The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis, „Pulmonary Pharmacology & Therapeutics”, 20 (3), 2007, s. 244–249, DOI: 10.1016/j.pupt.2006.01.003, PMID: 16530440 [dostęp 2021-08-18](ang.).
R.D.R.D.MannR.D.R.D. i inni, Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice, „BMJ (Clinical research ed.)”, 320 (7243), 2000, s. 1184–1186, DOI: 10.1136/bmj.320.7243.1184, PMID: 10784544, PMCID: PMC27362 [dostęp 2021-08-18](ang.).
PhilippeP.DevillierPhilippeP., NicolasN.RocheNicolasN., ChristopheCh.FaisyChristopheCh., Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review, „Clinical Pharmacokinetics”, 47 (4), 2008, s. 217–230, DOI: 10.2165/00003088-200847040-00001, PMID: 18336052 [dostęp 2021-08-18](ang.).
M.M.AugustinM.M., S.S.EhrleS.S., Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients, „Journal of the European Academy of Dermatology and Venereology: JEADV”, 23 (3), 2009, s. 292–299, DOI: 10.1111/j.1468-3083.2008.03034.x, PMID: 19438819 [dostęp 2021-08-18](ang.).
europa.eu
ema.europa.eu
European Medicines Agency Committee for Medicinal Products for HumanE.M.A.C.M.P.H.UseEuropean Medicines Agency Committee for Medicinal Products for HumanE.M.A.C.M.P.H., Aerius, INN: desloratadine. Assessment Report [online], 22 lutego 2007.
nih.gov
ncbi.nlm.nih.gov
Manjinder S.M.S.LallManjinder S.M.S. i inni, Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H1 Receptor Inverse Agonist, „Journal of Medicinal Chemistry”, 63 (13), 2020, s. 7268–7292, DOI: 10.1021/acs.jmedchem.0c00483, PMID: 32462865 [dostęp 2021-08-18](ang.).
Gai-ZhiG.Z.LiuGai-ZhiG.Z. i inni, Stereoselective synthesis of desloratadine derivatives as antagonist of histamine, „Bioorganic & Medicinal Chemistry”, 18 (4), 2010, s. 1626–1632, DOI: 10.1016/j.bmc.2009.12.061, PMID: 20110173 [dostęp 2021-08-18](ang.).
A.A.SabbahA.A., [The place of new antihistamines in allergy management. Apropos of desloratadine], „Allergie Et Immunologie”, 34 (10), 2002, s. 377–383, PMID: 12575624 [dostęp 2021-08-18](fr.).
MeltonM.AffrimeMeltonM. i inni, A pharmacokinetic profile of desloratadine in healthy adults, including elderly, „Clinical Pharmacokinetics”, 41 Suppl 1, 2002, s. 13–19, DOI: 10.2165/00003088-200241001-00003, PMID: 12169042 [dostęp 2021-08-18](ang.).
NancyN.HakoozNancyN., Isam I.I.I.SalemIsam I.I.I., Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males, „Biopharmaceutics & Drug Disposition”, 33 (1), 2012, s. 15–21, DOI: 10.1002/bdd.1770, PMID: 22271705 [dostęp 2021-08-18](ang.).
Inês CristinaI.C.Camelo-NunesInês CristinaI.C., New antihistamines: a critical view, „Jornal De Pediatria”, 82 (5 Suppl), 2006, S173–180, DOI: 10.2223/JPED.1552, PMID: 17136293 [dostęp 2021-08-18](port.).
KarstenK.WellerKarstenK., MarcusM.MaurerMarcusM., Desloratadine inhibits human skin mast cell activation and histamine release, „The Journal of Investigative Dermatology”, 129 (11), 2009, s. 2723–2726, DOI: 10.1038/jid.2009.134, PMID: 19516262 [dostęp 2021-08-18](ang.).
DamianD.TworekDamianD. i inni, The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis, „Pulmonary Pharmacology & Therapeutics”, 20 (3), 2007, s. 244–249, DOI: 10.1016/j.pupt.2006.01.003, PMID: 16530440 [dostęp 2021-08-18](ang.).
M.S.M.S.AshenagerM.S.M.S. i inni, Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines, „Journal of Investigational Allergology & Clinical Immunology”, 17 (1), 2007, s. 20–26, PMID: 17323859 [dostęp 2021-08-18](ang.).
R.D.R.D.MannR.D.R.D. i inni, Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice, „BMJ (Clinical research ed.)”, 320 (7243), 2000, s. 1184–1186, DOI: 10.1136/bmj.320.7243.1184, PMID: 10784544, PMCID: PMC27362 [dostęp 2021-08-18](ang.).
PhilippeP.DevillierPhilippeP., NicolasN.RocheNicolasN., ChristopheCh.FaisyChristopheCh., Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review, „Clinical Pharmacokinetics”, 47 (4), 2008, s. 217–230, DOI: 10.2165/00003088-200847040-00001, PMID: 18336052 [dostęp 2021-08-18](ang.).
M.M.AugustinM.M., S.S.EhrleS.S., Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients, „Journal of the European Academy of Dermatology and Venereology: JEADV”, 23 (3), 2009, s. 292–299, DOI: 10.1111/j.1468-3083.2008.03034.x, PMID: 19438819 [dostęp 2021-08-18](ang.).
R.E.R.E.GrubbeR.E.R.E., W.R.W.R.LumryW.R.W.R., R.R.AnolikR.R., Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis, „Journal of Investigational Allergology & Clinical Immunology”, 19 (2), 2009, s. 117–124, PMID: 19476015 [dostęp 2021-08-18](ang.).